Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.68 |
| ▸ | IDO1 | P14902 | 2/20 | 0.59 |
| ▸ | AGXT | P21549 | 2/20 | 0.59 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.55 |
| ▸ | PNMT | P11086 | 1/20 | 0.54 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42451 | 1.00 | — | — | |
| SCHEMBL29469769 | 1.00 | — | — | |
| Bromide SCHEMBL4208477 | 0.98 | TAAR1 (0.65) | TAAR1IDO1AGXTLOXL2PNMT | |
| Hydrochloric Acid SCHEMBL302987 | 0.98 | TAAR1 (0.65) | TAAR1IDO1AGXTLOXL2PNMT | |
| Iodide SCHEMBL31162584 | 0.98 | TAAR1 (0.65) | TAAR1IDO1AGXTLOXL2PNMT | |
| Iodide SCHEMBL28639359 | 0.98 | TAAR1 (0.65) | TAAR1IDO1AGXTLOXL2PNMT | |
| SCHEMBL27944031 | 0.86 | TAAR1 (0.53) | TAAR1IDO1AGXTLOXL2PNMT | |
| SCHEMBL235748 | 0.81 | TAAR1 (1.00) | TAAR1IDO1AGXTLOXL2MAOB | |
| SCHEMBL10422276 | 0.81 | LOXL2 (0.71) | TAAR1LOXL2PNMTENPP2SMN1; SMN2 | |
| SCHEMBL36008 | 0.81 | LOXL2 (0.71) | TAAR1LOXL2PNMTENPP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071588-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| EP-2247184-A1 | DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS | Glaxo Group Limited (GB) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009100167-A1 | DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| US-20090203677-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203677-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | PDE4A, PDE4B, PDE1A | TAAR1 890/4885IDO1 171/4885AGXT 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.